Kailera Therapeutics, Inc. Common Stock, Capital Shares Reserved for Future Issuance
Kailera Therapeutics, Inc. (KLRA) had Common Stock, Capital Shares Reserved for Future Issuance of 29.67 million shares as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Class of Stock Disclosures
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2026-08-12
- 2026-06-30: Common Stock, Capital Shares Reserved for Future Issuance 29.67M shares.
- 2026-03-31: Common Stock, Capital Shares Reserved for Future Issuance 100.08M shares.
- 2025-12-31: Common Stock, Capital Shares Reserved for Future Issuance 100.10M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2026-06-30 | 29.67M shares 10-Q · filed 2026-08-12 |
| 2026-03-31 | 100.08M shares 10-Q · filed 2026-05-26 |
| 2025-12-31 | 100.10M shares 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |